GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » Cash Flow from Others

OKUR (OnKure Therapeutics) Cash Flow from Others : $0.41 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics Cash Flow from Others?

OnKure Therapeutics's cash flow from others for the three months ended in Sep. 2024 was $-1.74 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2024 was $0.41 Mil.


OnKure Therapeutics Cash Flow from Others Historical Data

The historical data trend for OnKure Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OnKure Therapeutics Cash Flow from Others Chart

OnKure Therapeutics Annual Data
Trend Dec22 Dec23
Cash Flow from Others
- -

OnKure Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Others Get a 7-Day Free Trial -2.15 2.15 - - -1.74

OnKure Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.41 Mil.

OnKure Therapeutics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of OnKure Therapeutics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


OnKure Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.